Overview: Chronic Lymphocytic Leukemia Prognostic Panel
Introduction: The Chronic Lymphocytic Leukemia Prognostic Panel is a diagnostic tool designed to assess CLL prognosis using whole blood or bone marrow samples. In India, CLL prognosis varies widely (indolent to aggressive), with markers (TP53 mutated/deleted, unmutated IGHV, ZAP70/CD38 expression, elevated B2M, SF3B1) predicting survival and therapy response (e.g., BTK inhibitors for high-risk). High morbidity from under-prognostication in rural/low-SES patients, limited molecular testing, delayed risk-adapted treatment. Per hematology practices aligned with ICMR guidelines, the test employs NGS and flow for prognostic markers over 1-2 days with high accuracy, valuable for personalized management. This diagnostic falls under leukemia prognosis and targets CLL patients, addressing accurate stratification to guide watch-and-wait vs. therapy. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise prognosis and improving survival. Its blood/bone marrow-based approach ensures reliable detection.
Other Names: CLL Prog Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology/oncology/hematology, compliant with 2025 standards.
Historical Milestone: Prognostic marker panels; in India, expanding in hematology.
Purpose: The test assesses 6 parameters including TP53 to guide CLL prognosis, stratify risk, inform treatment decisions.
Test Parameters: 1. TP53, 2. IGHV, 3. ZAP70, 4. CD38, 5. B2M, 6. SF3B1.
Pretest Condition: No fasting required; patients should have confirmed CLL diagnosis.
Specimen: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred).
Medical History: Patients should provide details on CLL stage, symptoms, prior therapy.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of high-risk prognosis including progression, benefits of stratification, and minimal discomfort from blood/bone marrow draw.
Procedural Considerations: The test involves sample processing using NGS and flow by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low tumor burden can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: High-risk markers indicate aggressive disease, necessitating specialist input. Low-risk may require follow-up.
Specialist Consultation: Hematologists/oncologists should be consulted for management.
Additional Supporting Tests: FISH, Rai/Binet staging for confirmation.
Test Limitations: Covers selected markers; comprehensive approach required.
References: Indian Journal of Hematology 2024, CLL Studies India 2023.
